Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00067301 · ClinicalTrials.gov registry record · Phase 3
PUFA Augmentation in Treatment of Major Depression
A Phase 3 study, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- Completed
- Registry status
- Phase 3
- Development phase
- 60
- Enrollment target
NCT00067301: Completed Phase 3 study, sponsored by National Center for Complementary and Integrative Health (NCCIH).
NCT00067301 is a Phase 3 study that has completed, run by National Center for Complementary and Integrative Health (NCCIH). The registered enrollment target is 60 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00067301, a Phase 3 study, has completed, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if omega-3 fatty acid EPA will enhance and speed up response to antidepressant therapy with Celexa (Citalopram) in people suffering from Major Depressive Disorder. All patients will receive Celexa, 50% will receive EPA, 50% placebo EPA.
Interventions
- DRUG Citalopram
- DRUG Polyunsaturated Fatty Acids (PUFA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2003-09 |
| Est. Completion | 2007-04 |
| Phase | Phase 3 |
What the finished NCT00067301 record still lists
NCT00067301 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 2 interventions - of which Citalopram is the first listed.
NCT00067301 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00067301 about?
NCT00067301 is a clinical study titled "PUFA Augmentation in Treatment of Major Depression". The purpose of this study is to determine if omega-3 fatty acid EPA will enhance and speed up response to antidepressant therapy with Celexa (Citalopram) in people suffering from Major Depressive Disorder. All patients will receive Celexa, 50% will receive EPA, 50% placebo EPA.
What is the current status of trial NCT00067301?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2003-09. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00067301?
The interventions under investigation include: Citalopram (DRUG), Polyunsaturated Fatty Acids (PUFA) (DRUG).
Who is sponsoring clinical trial NCT00067301?
This trial is sponsored by National Center for Complementary and Integrative Health (NCCIH), which has 203 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00067301's enrollment target sits among peer trials
60 1804th of 2000 higher than 177 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia